Last reviewed · How we verify
MSPV4
MSPV4 is a recombinant meningococcal serogroup B, C, W, and Y conjugate vaccine that stimulates immune responses against multiple meningococcal serogroups.
MSPV4 is a recombinant meningococcal serogroup B, C, W, and Y conjugate vaccine that stimulates immune responses against multiple meningococcal serogroups. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups B, C, W, and Y.
At a glance
| Generic name | MSPV4 |
|---|---|
| Sponsor | CanSino Biologics Inc. |
| Drug class | Meningococcal conjugate vaccine |
| Target | Neisseria meningitidis serogroups B, C, W, Y polysaccharide antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MSPV4 is a multivalent meningococcal conjugate vaccine designed to provide protection against four major disease-causing serogroups of Neisseria meningitidis (B, C, W, and Y). The vaccine works by presenting bacterial polysaccharide antigens conjugated to a carrier protein, which enhances T-cell dependent immune responses and generates both antibody and cellular immunity against these serogroups.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis serogroups B, C, W, and Y
Common side effects
- Injection site pain/erythema
- Fever
- Myalgia
- Fatigue
Key clinical trials
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds (PHASE3)
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSPV4 CI brief — competitive landscape report
- MSPV4 updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI